ProQR Therapeutics (NASDAQ:PRQR) Now Covered by Oppenheimer

Research analysts at Oppenheimer began coverage on shares of ProQR Therapeutics (NASDAQ:PRQR) in a research report issued on Friday, MarketBeat.com reports. The brokerage set an “outperform” rating and a $15.00 price target on the biopharmaceutical company’s stock.

A number of other brokerages have also weighed in on PRQR. JMP Securities reaffirmed a “market outperform” rating and issued a $8.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Raymond James raised shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their target price for the stock from $6.00 to $14.00 in a research note on Tuesday, October 29th. StockNews.com downgraded ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $4.00 price objective on shares of ProQR Therapeutics in a research report on Thursday, December 12th. One research analyst has rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, ProQR Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $8.83.

ProQR Therapeutics Price Performance

NASDAQ PRQR opened at $2.42 on Friday. ProQR Therapeutics has a one year low of $1.61 and a one year high of $4.62. The firm has a market cap of $197.67 million, a P/E ratio of -7.56 and a beta of 0.30. The stock’s 50-day moving average is $3.23 and its 200-day moving average is $2.51.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Privium Fund Management B.V. boosted its holdings in shares of ProQR Therapeutics by 0.9% in the 3rd quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock valued at $10,251,000 after buying an additional 51,663 shares during the last quarter. OneDigital Investment Advisors LLC raised its position in ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 15,550 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in ProQR Therapeutics by 14.2% in the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 7,300 shares during the last quarter. 32.65% of the stock is currently owned by institutional investors.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).